Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Paricalcitol

Generic Name: Paricalcitol

Brand Names: Zemplar

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₄O_₃

CAS Number: 131918-61-1

Unique Ingredient Identifier: 6702D36OG5

Overview

Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

Background

Indication

For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4

Associated Conditions

Secondary Hyperparathyroidism (SHPT)

Clinical Trials

A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis

Phase 3

Completed

Posted: 2011/06/27

Sponsor:AbbVie (prior sponso...

ID:NCT01382212

Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism

Phase 3

Completed

Posted: 2011/04/26

Sponsor:AbbVie (prior sponso...

ID:NCT01341782

Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy

Phase 4

Completed

Posted: 2011/04/08

Sponsor:

Peter Rossing

ID:NCT01331317

Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients

Phase 4

Completed

Posted: 2010/12/23

Sponsor:

Ural State Medical U...

ID:NCT01265615

Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism

Phase 2

Completed

Posted: 2010/10/13

Sponsor:

Mario Negri Institut...

ID:NCT01220050

FDA Approved Products

Zemplar

Manufacturer:AbbVie Inc.

Route:ORAL

Strength:2 ug in 1 1

Approved: 2022/11/22

NDC:0074-9037

Paricalcitol

Manufacturer:West-Ward Pharmaceuticals Corp

Route:INTRAVENOUS

Strength:2 ug in 1 mL

Approved: 2018/09/17

NDC:0143-9625

Paricalcitol

Manufacturer:West-Ward Pharmaceuticals Corp

Route:INTRAVENOUS

Strength:5 ug in 1 mL

Approved: 2018/09/17

NDC:0143-9624

Paricalcitol

Manufacturer:Bionpharma Inc.

Route:ORAL

Strength:4 ug in 1 1

Approved: 2023/12/27

NDC:69452-147

PARICALCITOL

Manufacturer:Eugia US LLC

Route:INTRAVENOUS

Strength:5 ug in 1 mL

Approved: 2023/11/09

NDC:55150-213

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy